|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Jean-Paul Clozel||CEO & Director||N/D||N/D||1955|
|Mr. André C. Muller||Exec. VP & CFO||N/D||N/D||1963|
|Dr. Martine Clozel||Exec. VP & Chief Scientific Officer||N/D||N/D||1955|
|Mr. Andrew C. Weiss||Sr. VP and Head of Investor Relations & Corp. Communications||N/D||N/D||1968|
|Dr. Guy Braunstein||Exec. VP & Head of Global Clinical Devel.||N/D||N/D||1956|
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. The company has collaboration agreements with Johnson & Johnson to jointly develop and commercialize aprocitentan and its derivative compounds or products; Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy; and collaboration agreement with ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
L'ISS Governance QualityScore di Idorsia Ltd al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.